Replies to post #538506 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

The Phase 3 trial from the JAMA article is linked to in the article I believe. I’ve linked to it below and yes, there is no Keytruda in the DCVax-L trial that is in the JAMA article. DCVax-L extended OS, without a combination therapy for both nGBM and rGBM.

This is the Phase 3 https://clinicaltrials.gov/ct2/show/NCT00045968

Those that you linked to are follow-on trials and other trials. One is the combination trial with Keytruda and the other is a trial with various types of brain tumors, not just GBM and they used the adjuvants there, including Poly ICLC, a TLR 3 Agonist, which seems to trigger a very strong reaction and may get the numbers of patients doing well with DCVax-L up quite significantly, and may get the numbers going to 5 years without recurrence up significantly. We have to wait for the final numbers, but an earlier, Phase 2 smaller trial had strong results with significance for which there was a published paper.

Hence the adjuvant poly ICLC is also used in the combination trial with Keytruda.